Buscar





Buscar





Mercado
/
Acciones
/
nasdaq-incy
/

Incyte Corp

INCY

Añadir a la lista de seguimiento

97.844USD

-1.286-1.30%

Horarios del mercado （ET）Cotizaciones retrasadas 15 min

19.42BCap. mercado

13.41P/E TTM



Incyte Corp

97.844

-1.286-1.30%

Descripción general Finanzas Discusiones Análisis Compañía

Descripción general

Finanzas

Discusiones

Análisis

Compañía

Más Datos de Incyte Corp Compañía

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.

Información de Incyte Corp



Símbolo de cotizaciónINCY

Nombre de la empresaIncyte Corp

Fecha de salida a bolsaDec 06, 1993

Director ejecutivoMeury (Bill)

Número de empleados2617

Tipo de seguridadOrdinary Share

Fin del año fiscalDec 06

Dirección1801 Augustine Cut-Off

CiudadWILMINGTON

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal19803

Teléfono13024986700

Sitio Webhttps://www.incyte.com/

Símbolo de cotizaciónINCY

Fecha de salida a bolsaDec 06, 1993

Director ejecutivoMeury (Bill)

Ejecutivos de Incyte Corp



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Herve Hoppenot

Director

1.06M

-34.96%

Mr. Julian C. Baker

Independent Chairman of the Board

278.77K

Mr. Paul J. Clancy

Independent Director

141.89K

-4.08%

Mr. Jean-Jacques Bienaime ,

Independent Director

138.99K

-4.16%

Dr. Pablo J. Cagnoni

President - Research and Development

112.45K

+68.45%

Dr. Katherine A. High, M.D.

Independent Director

75.30K

+12.24%

Mr. Thomas R. Tray

Vice President - Finance and Chief Accounting Officer, (Principal Accounting Officer), Principal Financial Officer

70.94K

+71.74%

Dr. Otis W. Brawley, M.D.

Independent Director

59.31K

+15.54%

Dr. Susanne Schaffert, Ph.D.

Independent Director

47.17K

+19.54%

Mr. Lee Heeson

Executive Vice President - Incyte, International

38.04K

-0.29%

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Mr. Herve Hoppenot

Director

1.06M

-34.96%

Mr. Julian C. Baker

Independent Chairman of the Board

278.77K

Mr. Paul J. Clancy

Independent Director

141.89K

-4.08%

Mr. Jean-Jacques Bienaime ,

Independent Director

138.99K

-4.16%

Dr. Pablo J. Cagnoni

President - Research and Development

112.45K

+68.45%

Dr. Katherine A. High, M.D.

Independent Director

75.30K

+12.24%

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de abr

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

JAKAFI revenues

3.09B

60.15%

OPZELURA revenues

678.46M

13.20%

JAKAVI product royalty revenues

457.73M

8.90%

NIKTIMVO revenues

151.64M

2.95%

Milestone and contract revenues

150.00M

2.92%

Otro

610.91M

11.88%

Por regiónUSD

Nombre

Ganancia

Proporción

United States

4.80B

93.36%

Europe

323.73M

6.30%

Other countries

17.57M

0.34%

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

JAKAFI revenues

3.09B

60.15%

OPZELURA revenues

678.46M

13.20%

JAKAVI product royalty revenues

457.73M

8.90%

NIKTIMVO revenues

151.64M

2.95%

Milestone and contract revenues

150.00M

2.92%

Otro

610.91M

11.88%

Estadísticas de accionistas

Actualizado: dom., 10 de may

Accionistas

Tipos de accionistas

Accionistas

Proporción

Baker Bros. Advisors LP

15.45%

Dodge & Cox

6.64%

BlackRock Institutional Trust Company, N.A.

5.99%

Vanguard Capital Management, LLC

5.47%

State Street Investment Management (US)

4.83%

Otro

61.62%

Accionistas

Proporción

Baker Bros. Advisors LP

15.45%

Dodge & Cox

6.64%

BlackRock Institutional Trust Company, N.A.

5.99%

Vanguard Capital Management, LLC

5.47%

State Street Investment Management (US)

4.83%

Otro

61.62%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

38.80%

Investment Advisor/Hedge Fund

38.57%

Hedge Fund

18.89%

Pension Fund

4.47%

Research Firm

2.12%

Individual Investor

1.92%

Bank and Trust

1.13%

Sovereign Wealth Fund

0.71%

Family Office

0.36%

Participación institucional



Actualizado: dom., 5 de abr

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2026Q1

1617

209.33M

104.84%

-3.76M

2025Q4

1548

207.27M

105.58%

-1.73M

2025Q3

1425

204.09M

103.95%

+86.81K

2025Q2

1423

201.60M

103.23%

-197.50K

2025Q1

1457

199.01M

102.81%

-12.15M

2024Q4

1448

191.80M

99.11%

-19.23M

2024Q3

1401

192.85M

100.02%

-35.92M

2024Q2

1385

209.06M

108.78%

-39.98M

2024Q1

1357

227.85M

101.54%

-21.15M

2023Q4

1323

228.89M

102.19%

-14.49M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

Baker Bros. Advisors LP

30.74M

15.45%

Feb 06, 2026

Dodge & Cox

13.26M

6.66%

-670.67K

-4.81%

Dec 31, 2025

BlackRock Institutional Trust Company, N.A.

11.96M

6.01%

+434.14K

+3.77%

Dec 31, 2025

State Street Investment Management (US)

9.66M

4.85%

-20.39K

-0.21%

Dec 31, 2025

AQR Capital Management, LLC

6.72M

3.38%

-1.20M

-15.19%

Dec 31, 2025

Geode Capital Management, L.L.C.

4.99M

2.51%

+506.84K

+11.30%

Dec 31, 2025

Renaissance Technologies LLC

3.98M

-549.80K

-12.14%

Dec 31, 2025

LSV Asset Management

3.93M

1.98%

-52.34K

-1.31%

Dec 31, 2025

ETFs relacionados



Actualizado: sáb., 6 de dic

Nombre

Proporción

Invesco Biotechnology & Genome ETF

5.42%

iShares Genomics Immunology and Healthcare ETF

5.11%

First Trust NYSE Arca Biotechnology Index Fund

3.75%

Bushido Capital US Equity ETF

2.47%

AAM Sawgrass US Large Cap Quality Growth ETF

2.44%

First Trust Health Care Alphadex Fund

2.4%

VanEck Biotech ETF

2.34%

Alger Russell Innovation ETF

2.18%

Virtus LifeSci Biotech Products ETF

2.16%

State Street SPDR S&P Biotech ETF

2.13%

Invesco Biotechnology & Genome ETF

Proporción5.42%

iShares Genomics Immunology and Healthcare ETF

Proporción5.11%

First Trust NYSE Arca Biotechnology Index Fund

Proporción3.75%

Bushido Capital US Equity ETF

Proporción2.47%

AAM Sawgrass US Large Cap Quality Growth ETF

Proporción2.44%

First Trust Health Care Alphadex Fund

Proporción2.4%

VanEck Biotech ETF

Proporción2.34%

Alger Russell Innovation ETF

Proporción2.18%

Virtus LifeSci Biotech Products ETF

Proporción2.16%

State Street SPDR S&P Biotech ETF

Proporción2.13%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Sin datos

División de acciones



Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

Fecha

Fecha ex-dividendo

Tipo

Relación

Sin datos

KeyAI

